ganirelix acetate diacetate sold brand names orgalutran antagon among others injectable competitive gonadotropinreleasing hormone antagonist gnrh antagonist primarily used assisted reproduction control ovulation drug works blocking action gonadotropinreleasing hormone gnrh upon pituitary thus rapidly suppressing production action lh fsh ganirelix used fertility treatment prevent premature ovulation could result harvesting eggs immature used procedures vitro gnrh agonists also sometimes used reproductive therapy well treat disorders involving sexsteroid hormones one advantage using gnrh antagonists repeated administration gnrh agonists results decreased levels gonadotropins sex steroids due desensitization pituitary avoided using gnrh antagonists success ganirelix reproductive therapy shown comparable using gnrh ganirelix used fertility treatment drug women specifically used prevent premature ovulation people ovaries undergoing fertility treatment involving ovarian hyperstimulation causes ovaries produce multiple eggs premature ovulation occurs eggs released ovaries may immature used invitro fertilization ganirelix prevents ovulation triggered injecting human chorionic gonadotrophin ganirelix administered subcutaneous injection µg per day mid late follicular phase patients menstrual cycle treatment start day start ovarian stimulation mean duration use five preferably subcutaneous injections delivered upper leg patient trained themself continued use drug take place administration hcg begins hcg administration begun sufficient number follicles developed due effects endogenous exogenously administered follicle stimulating ganirelix used women already pregnant onset pregnancy must ruled administered women using ganirelix breast feed known whether ganirelix excreted breast clinical studies shown common side effect slight reaction site injection form redness sometimes clinical studies shown one hour injection incidence least one moderate severe local skin reaction per treatment cycle patients treated ganirelix patients treated subcutaneously gnrh agonist local reactions generally disappear within hours reported side effects known associated ovarian hyperstimulation including gynecological abdominal pain headache vaginal bleeding nausea gastrointestinal abdominal pain rare cases less user hypersensitivity ganirelix cause anaphylactoid reactions likely due followup analysis ganirelix done marketing authorisation holder compared number congenital malformations individuals whose mothers treated ganirelix compared individuals whose mothers treated gnrh agonist total number congenital malformations higher ganirelix group gnrh agonist group vs falls within range normal incidence congenital malformations current data suggest ganirelix increases incidence congenital malformations anomalies important differences frequency ectopic pregnancies miscarriage noted use currently studies done assess possible drugdrug interactions ganirelix ganirelix synthetic peptide works antagonist gonadotropinreleasing hormone gnrh ganirelix acetate injection ganirelix competitively blocks gnrh receptors pituitary gonadotroph quickly resulting suppression gonadotropin suppression easily reversed discontinuation ganirelix administration ganirelix significantly higher receptor binding affinity kd nm gnrh kd ganirelix given healthy adult females steadystate serum concentrations reached average three days ganirelix acetate injection study administering ganirelix healthy adult females found mean sd elimination halflife hours volume distributionabsolute bioavailability vdf liters maximum serum concentration cmax ngml time maximum concentration tmax hours one µg injection ganirelix resulted mean absolute bioavailability ganirelix derived gnrh amino acid substitutions made positions european commission gave marketing authorization ganirelix throughout european union nv organon may httpsenwikipediaorgwikiganirelix